In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

The Endgame on Oncology Endpoints

Executive Summary

The annual ASCO meeting, held in Chicago this year, provided a forum for investigators to discuss the merits of continued use of progression-free survival as an endpoint in oncology clinical trials. Phase III data from Roche/Genentech's Avastin in metastatic breast cancer sparked debate.
Advertisement

Related Content

Provenge Fails To Meet Interim Study Endpoint, But Dendreon Will Press On
Cancer Vaccine R&D Makes Strides With Better Endpoints, Patient Selection
Cancer Vaccine R&D Makes Strides With Better Endpoints, Patient Selection
Avastin Misses Overall-survival Endpoint In Lung Cancer
Is Faster Better? Senators Question Surrogate Endpoints, Fast Track Status
FDA Panel Views On PFS Endpoint For Avastin Could Impact Fate Of Other First-Line Cancer Drugs
Survival Endpoints, Rigorous Phase IIs May Boost Cancer Vaccines’ Success
FDA Cancer Endpoint Guidance Abandons Placebos, Moves Beyond Survival

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

IV003140

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel